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mmunogenicity of interleukin 12 and DNA vaccine prime-
CG boost against Mycobacterium tuberculosis
. Bao ∗, L. Gao, Y. Bao
Sichuan University, Chengdu, China
Background: BCG as an only effective vaccine to TB
layed variable efﬁcacy. New vaccination strategies are
equired. We used interleukin 12 with the combined
NA prime- BCG boost strategies to observe whether the
mmunogenicity of vaccines against M.Tuberculosis would be
mproved.
Methods: Plasmid pcDNA- Ag85A and pc-Esat-6 were
onstructed for vaccination. The mice were divided into
immunity groups: BCG group(1), DNA/BCG group(2),
NA + IL- 12/BCG group(3) and DNA/BCG+ IL-12 group(4).
ll mice received three immunizations at 2- week interval
or prime-boost experiments, animals were twice vacci-
ated intramuscular injection with combined DNA (Ag85A
nd ESAT-6) or mixed DNA-IL-12 and combined DNA, then
oosted with BCG or mixed with DNA-IL-12 and BCG. ELISA
as used to determine IgG antibody speciﬁcity and the
roliferative responses of lymphocytes and the phenotype
as detected by ﬂow cytometry. Production of INF- was
etected at 4-week, 6-week, and 8-week after boost.
Results: The antibody titer of group 1, group 2, group 3
nd group4 showed a positive reaction. Group3 and 4 com-
ared with group2 and 1, induced high antibody titer. The
ntibody titer of all four groups increased gradually, and
chieved a higher level at 8 week after booster. Group 1,
roup 2, group 3and group4 all showed signiﬁcant differ-
nce of proliferative responses (P < 0.05). Group 3and group
were much higher that group 2 and group1 (P < 0.05).
The group 3 and the group 4 induced stronger antigen-
peciﬁc IFN-. The mean IFN- responses of group 3and the
roup 4 were not only signiﬁcantly higher than group PBS
P < 0.01) but also higher than group 2and group 1 (P < 0.05).
he mean percentage of CD4 + and CD8+ T cells vaccinated
ith DNA/BCG+IL-12, DNA+IL-12/BCG, DNA/BCG, or BCG
ere signiﬁcantly higher compared to group PBS(P < 0.05).
higher mean percentage of CD4+ and CD8+ T cells
ere observed in mice vaccinated with DNA+ IL-12/BCG or
NA/BCG+ IL-12 when compared to the DNA/BCG or BCG
roups.
Conclusion: Our results showed that the strategy of using
uman interleukin 12(IL-12) associate DNA priming followed
y BCG boosting is an effective way to increase the immuno-
enicity of tuberculosis, not only increasing cell immunity
ut also maintaining a stable humoral immunity.
oi:10.1016/j.ijid.2010.02.609
3.007
he role of inactivated polio vaccine (IPV) in achieving
olio eradication in India
. BhattiBraun School of Public Health, 110070, India
Background: Since ancient times polio has lamed millions
f young children before they had learned to walk. The
w
r
dternational Congress on Infectious Diseases (ICID) Abstracts
orld Health Organization since 1988 is spearheading the
lobal efforts to eradicate poliomyelitis. The global initia-
ive to eradicate the disease has been successful in reducing
he incidence by 99% and it has prevented more than 5
illion cases of polio in past 21 years. The disease has
een eradicated throughout the western hemisphere and
n most developing nations by use of the Sabin Oral Polio
accine. At the present crucial end stage of polio eradi-
ation, the wild virus is circulating in Afghanistan, India,
igeria and Pakistan. The studies in developing countries
ave demonstrated that even after more than 3 doses of
PV, the immune response generated in children is not sat-
sfactory and not all the children seroconvert. Studies have
oncluded that that OPV/IPV sequential schedule generate
ar superior humoral and intestinal immune response. It is
herefore essential for the policy makers to consider the role
hat could be played by the sequential IPV/OPV schedule in
chieving the goal of polio eradication for this important
nternational public health challenge.
Methods: To achieve the objectives, we used peer
eviewed journal articles published since 01-01-1985 till 31-
7-2009. The articles were searched via Pub Med and EMBASE
lectronic data base system using key words/phrases. The
riteria used for limiting the search while using PubMed and
mbase have been described in Table: 1. The references of
he selected articles were also searched for additional liter-
ture. The seroconversion rates among the study population
fter OPV only, IPV only and sequential OPV/IPV schedule
ere compared with each other.
able: 1 Limiting criteria used for literature search on
ubMed and Embase
imiting Criteria PubMed EMBASE
ull Text
√
ate 01/01/1985
to
31/07/2009
01/01/1985
to
31/07/2009
anguage English English
ype of Studies Included
Randomized Controlled Trials
√ √
Analysis
√ √
Practice Guidelines
√
X
Reviews
√ √
Controlled Clinical Trial
√ √
ge
New-Born
√ √
Infant
√ √
Pre-School Child 2-5 Years
√
X
1-6 Year X
√
Criterias for Literature Search
Results: In the various setting in the developing countries
t was observed that the seroconversion rates among those
hildren receiving IPV/OPV sequential schedule was higher
han OPV only schedule.
Conclusion: The rationales for use of sequential IPV/OPV
chedule in current setting are (1) It will ﬁll the existing
mmunity gap rapidly (2) It will reduce the excretion of vac-ill be reduced. (4) It will also allow strengthening of the
outine immunization services by states.
oi:10.1016/j.ijid.2010.02.610
